Company research / QNRX
Quoin Pharmaceuticals Ltd. (QNRX)
- Sector Manufacturing
Key ratios (year ended 2025-12-31)
-120.5%
Return on year-end equity
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.
Annual financials
| Period ended | TTM to 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a | $0 | $0 | $0 |
| R&D Expense | $12.44M | $9.80M | $3.60M | $3.31M | $2.67M | $1.56M | $244.2K | $45.6K |
| Net Income | -$18.67M | -$15.80M | -$8.96M | -$8.69M | -$9.38M | -$21.46M | -$2.10M | -$1.56M |
| EPS (Diluted) | n/a | n/a | n/a | n/a | n/a | -$0.01 | -$0.70 | -$0.52 |
| Total Assets | $11.97M | $20.39M | $15.71M | $12.17M | $14.46M | $9.36M | $1.38M | n/a |
| Total Liabilities | $8.04M | $7.27M | $6.50M | $6.51M | $7.05M | $8.70M | $7.99M | n/a |
| Shareholders' Equity | $3.93M | $13.12M | $9.20M | $5.66M | $7.41M | $657.0K | -$6.61M | -$4.51M |
| Cash & Equivalents | $3.85M | $3.82M | $3.62M | $2.40M | $2.86M | $7.48M | $323.8K | n/a |
| Operating Cash Flow | -$15.27M | -$13.54M | -$7.86M | -$7.86M | -$8.48M | -$5.72M | -$1.34M | -$1.30M |
| Shares Outstanding | 70.29M | 52.44M | 8.95M | 987.2K | 403.9K | 3.35B | n/a | n/a |
| Weighted Average Diluted Shares | n/a | n/a | n/a | n/a | n/a | 1.58B | n/a | n/a |
| EPS (Basic) | n/a | n/a | n/a | n/a | n/a | -$0.01 | -$0.70 | -$0.52 |